ANDA review speeds up
This article was originally published in The Tan Sheet
Executive SummaryFDA is approving abbreviated new drug applications at a faster pace in fiscal 2004 than in FY 2003. From October 2003 through August 2004, the agency's Office of Generic Drugs approved 289 original ANDAs - five more than were cleared in all of FY 2003. The agency also tentatively approved 83 applications in the first 11 months of FY 2004, compared to 89 tentative approvals in all of FY 2003. FDA attributes the improvements to increased staff, better training and changes in procedures, which allow reviewers to verbally communicate application deficiencies to sponsors. FDA anticipates that FY 2004 also will show a surge in the total number of generic applications received, as well as a decline in the average review time for ANDAs...
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.